Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foralumab in Early Symptomatic Alzheimer's Disease
NCT06489548Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of foralumab in Alzheimer's disease (AD), sponsored by Brigham and Women's Hospital. Started Sep 2025; status: recruiting.
02
Drugs
foralumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06489548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06489548.